Compare PLUG & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLUG | VCEL |
|---|---|---|
| Founded | 1997 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.4B |
| IPO Year | 1999 | 1996 |
| Metric | PLUG | VCEL |
|---|---|---|
| Price | $2.15 | $37.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | $2.31 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 54.0M | 428.3K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 47.01 | ★ 60.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $709,919,000.00 | $276,259,000.00 |
| Revenue This Year | $26.67 | $19.40 |
| Revenue Next Year | $8.09 | $18.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 12.90 | ★ 16.45 |
| 52 Week Low | $1.52 | $28.95 |
| 52 Week High | $4.58 | $49.32 |
| Indicator | PLUG | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 44.82 | 27.12 |
| Support Level | $1.89 | $35.45 |
| Resistance Level | $2.50 | $38.01 |
| Average True Range (ATR) | 0.10 | 1.12 |
| MACD | 0.00 | -0.34 |
| Stochastic Oscillator | 16.07 | 1.38 |
Plug Power Inc is building an end-to-end green hydrogen ecosystem, from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.